Obstructive Lung Disease
-
Biologic therapies in asthma: From foundation to the future
Biologic therapies are changing severe asthma management, shifting the goal from control to remission. Diego J. Maselli, MD, FCCP; Dharani Narendra, MD, FCCP; and Megan Conroy, MD, MAEd, FCCP, explore their impact in this installment of Clinical Outlook in Pulmonology.
-
Intranasal saline improves symptoms in children with sleep-disordered breathing
The results of the MIST+ trial support the conclusion that saline is as effective as corticosteroid in managing symptoms of OSDB, said lead author Gillian Nixon, MD.
-
Adult bronchiectasis guidelines updated to reflect emerging evidence on disease identification and management
New bronchiectasis recommendations from the European Respiratory Society reflect a shift toward individualized, risk-based care, recognizing diverse inflammatory and microbiologic profiles. The guidelines emphasize early identification of high-risk patients, multidimensional assessment, and universal airway clearance training.
-
Data support use of nirsevimab prophylaxis to reduce RSV hospitalization risk for infants
Retrospective data show significantly fewer infants were hospitalized for RSV after nirsevimab became available. Among the RSV hospitalizations that occurred during that time period, 75% were in infants who had not received nirsevimab.
-
While still elevated, early 2026 data show US influenza A cases stabilizing or decreasing
Infectious disease expert Frederick G. Hayden, MD, said timely use of antivirals for prophylaxis and treatment can minimize the impact of this flu season, which has seen a significant mismatch between vaccines and the circulating strain.
-
New fund empowers CHEST Networks to pursue their most impactful ideas
The Networks Advancement Fund offers financial support for projects that directly advance CHEST’s philanthropic pillars while furthering the mission of an individual Network.
-
GLP-1RAs may trigger chronic cough for some patients with diabetes
Surprisingly, the association between GLP-1 medications and chronic cough was stronger in patients without an existing diagnosis of gastroesophageal reflux disease.
-
Optimal synergy: Coupling smart wearable devices, sensors with AI algorithms
Coupling noninvasive wearable devices with AI-enabled data analytics helps to address two key challenges: health care access and improvement of patient-centric care.
-
GLP-1RAs may reduce risk of asthma exacerbations for adolescents with obesity
Pulmonologist Farrukh Abbas, MD, said this observational study generates a hypothesis about the anti-inflammatory benefits of GLP1-RA medications in patients with asthma and obesity that needs to be confirmed in trials.
-
GOLD 2026 updates in global strategy for diagnosis, management, and prevention of COPD
The GOLD 2026 report advances a contemporary model of COPD as a modifiable, biologically active disease requiring individualized and proactive management.
-
2026 GOLD report provides key updates on COPD exacerbations, case finding
Gerard J. Criner, MD, FCCP, a member of the GOLD Science Committee, said the latest insights aim to improve patient outcomes and bring awareness to treating COPD exacerbations.
-
AI-enabled approaches poised to transform diagnosis, management of lung diseases
Experts explore how AI-based tools can be used to bridge diagnostic challenges and address unmet needs in chronic respiratory disease care.
